HIV/AIDS

Researchers have long associated HIV exposure with a heightened risk of congenital cytomegalovirus in infants. However, new research finds the risk is highest if HIV is contracted during the pregnancy.

The 4th generation VITROS Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator has been approved by the FDA for use on the VITROS 5600 Integrated System.

Adolescents living with HIV suffer fewer disease-related symptoms when they and a family member plan for end-of-life care.

When providers fail to recognize and combat stigma in their ranks, undiagnosed persons with HIV may go unidentified and fail to get quality care and treatment.

Hispanic/Latina women in the US access HIV treatment at same rates as men despite facing greater challenges.

Statistical analysis reveals cardiac effects of individual antiretrovirals in combination treatments for children infected with HIV perinatally.

The investigators determined that hepatitis C co-infection increased risk for all-cause mortality in patients with HIV receiving antiretroviral treatment by 4.3%.

Only about half of people living with HIV who were released from prison or jail remained in HIV care 1-2 years after release.

A pair of new studies suggests combining 2 new broadly neutralizing antibodies might be an effective way to achieve long-term HIV viral suppression without the use of antiretroviral therapy.

New research finds a mobile-optimized HIV-prevention program works, but its impact dissipates with time.

Just 1 of 72 resident physicians surveyed at a North Carolina medical school had ever prescribed PrEP to a patient at high risk of contracting HIV.

A Dallas-based study found that an adult hospital with a universal screening policy was far more likely to provide screenings to high-risk patients aged 13 or older.

DOR/3TC/TDF demonstrates noninferior efficacy and safety compared with continuing other ART regimens in a phase 3 trial.

Investigators analyzed data from PrEP-eligible patients at the New York City Health + Hospital/Bellevue which showed that women and minority patients were less likely to be prescribed PrEP for HIV prevention.

Race and sex can play a role in the annual BMI gain for patients with HIV who are receiving certain antiretroviral therapy combinations.

An intervention of scheduling an appointment and contacting the patient successfully increased re-engagement among patients with HIV who had not had a primary care visit in the previous 6 months.

Approximately 30% of annual HIV infections are caused by the subset of individuals unaware of their serostatus, and HCV rates have nearly tripled since 2011.

New data from the CDC suggests young gay and bisexual men are receiving HIV diagnoses at higher rates than their older peers, but it may be due in part to increased testing.

A modeling analysis suggests state officials in Indiana could have prevented upwards of 95% of the HIV cases in a 2014 outbreak.

When expectant mothers started antiretroviral therapy before pregnancy, their HIV-exposed but uninfected infants had lower infection risk than infants whose mothers started ART during pregnancy.

The PrEPmate support intervention increased visit attendance and PrEP adherence among young men who have sex with men.

New research finds two-thirds of gay and bisexual men who know about pre-exposure prophylaxis have a positive view of it. The challenge is that only 4% are using it.

A small number of patients with HIV are able to maintain viral control even after they stop taking antiretroviral therapy.

Switching to the smallest complete daily pill for HIV from other regimens with different components of the same drug classes proved advantageous for patients with HIV, treating the infection with less adverse effects.

Symptoms of cardiovascular disease, including intima-media thickness and coronary artery calcium, were more common in patients with HIV and cytomegalovirus.

Evidence from a number of countries suggests that America’s expansion of opioid addiction treatment programs will pay dividends in curbing rates of HIV transmission among people who inject drugs.

Addressing housing arrangements during a medical visit may be as important as addressing blood pressure or blood sugar levels.

A daily dose of aspirin could reduce HIV transmission rates by reducing inflammation and thus the number of HIV target cells in the female genital tract.

Flexible, individualized counseling for HIV patients who also use injection drugs also resulted in improved viral suppression.

The risk of acute coronary syndrome recurring after hospitalization was not found to be increased in individuals infected with HIV.